"It is the antigen(s), stupid" and other lessons from over a decade of vaccitherapy of human cancer.

Seminars in Immunology
Matthew R Buckwalter, Pramod K Srivastava

Abstract

The lessons are: (a) human cancers certainly respond to immunological manipulations. Efforts at human cancer immunotherapy are therefore worthwhile. (b) Prophylaxis is very different from therapy of pre-existing disease, and hence much enthusiasm should not be derived from successful prophylaxis studies. Even in case of infectious agents against which robust prophylaxis is routinely achieved, therapy is nearly impossible once the disease has established. (c) Studies with appropriate cancer models of mice and rats are useful. The notion that it is easy to cure cancers in mice is generally advanced the most confidently by those who have never cured a mouse of cancer by immunotherapy. (d) With a nod to James Carville, it is the antigen(s), stupid! We still do not know the identity of protective tumor antigens. If any lesson can be drawn at all, it may well be that cancer immunotherapy must move away from the one-shoe-fits-all therapeutic models of chemotherapy and must move to individualized approaches. (e) All targets are equal, but some are more equal than others. The key is specificity for cancer. That does not necessarily mean specificity for cancer cells. (f) Vaccitherapy must be attempted preferably in the minimal residual d...Continue Reading

References

Jan 1, 1992·The Journal of Experimental Medicine·S SinghH Schreiber
Sep 1, 1990·Proceedings of the National Academy of Sciences of the United States of America·P Garin-ChesaW J Rettig
Mar 1, 1988·Immunology Today·P K Srivastava, L J Old
Aug 15, 1995·Proceedings of the National Academy of Sciences of the United States of America·P G CoulieT Boon
Jun 10, 1997·Proceedings of the National Academy of Sciences of the United States of America·H IkedaH Shiku
Mar 29, 2001·Proceedings of the National Academy of Sciences of the United States of America·T Matsutake, P K Srivastava
Apr 17, 2003·Proceedings of the National Academy of Sciences of the United States of America·F Stephen HodiGlenn Dranoff
May 25, 2004·Journal of Leukocyte Biology·Steven E FinkelsteinNicholas P Restifo
Jul 6, 2004·Immunological Reviews·Eli Gilboa, Johannes Vieweg
Oct 26, 2005·Proceedings of the National Academy of Sciences of the United States of America·Volker LennerzThomas Wölfel
Nov 16, 2005·International Journal of Cancer. Journal International Du Cancer·Mitsuhiro TakenoyamaPierre G Coulie
Jan 18, 2006·Annual Review of Medicine·Thomas A Waldmann
Feb 17, 2006·The New England Journal of Medicine·Helen GogasJohn M Kirkwood
Apr 14, 2006·Cancer Immunology, Immunotherapy : CII·Jon A Kyte, Gustav Gaudernack
Jun 6, 2007·European Journal of Immunology·Karin L HeckmanLarry R Pease
Aug 10, 2007·Nature Reviews. Cancer·Kristopher K Frese, David A Tuveson
Aug 28, 2007·Nature Reviews. Cancer·Tracy Vargo-Gogola, Jeffrey M Rosen
Oct 19, 2007·British Journal of Haematology·Brian J ScaglioneElizabeth S Raveche
Jan 25, 2008·Proceedings of the National Academy of Sciences of the United States of America·Margaret K CallahanPramod K Srivastava
Feb 22, 2008·Proceedings of the National Academy of Sciences of the United States of America·F Stephen HodiGlenn Dranoff

❮ Previous
Next ❯

Citations

Mar 13, 2010·Journal of Oncology·Niels HalamaDirk Jaeger
Sep 24, 2014·The Journal of Experimental Medicine·Fei DuanPramod K Srivastava
Jul 27, 2011·Cancer Immunology, Immunotherapy : CII·Xiaoli YanSongdong Meng
Jun 18, 2010·Expert Review of Anticancer Therapy·Cara K FraserJohn D Hayball
Jun 2, 2014·Hematology/oncology Clinics of North America·Patrick A OttGlenn Dranoff
Feb 27, 2013·Clinics in Dermatology·Tatiana BlanchardFei Duan
Feb 12, 2010·The Journal of Investigative Dermatology·Jennifer K BroomIan H Frazer
May 23, 2014·Immunologic Research·David M LubaroffRichard D Williams
Oct 20, 2009·European Journal of Immunology·Zhen LiuSongdong Meng
Jul 10, 2010·Journal of Biomedicine & Biotechnology·Anastas PashovThomas Kieber-Emmons
Apr 24, 2012·EuroIntervention : Journal of EuroPCR in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology·Paul FeferBradley H Strauss
Jun 20, 2020·Journal of Leukocyte Biology·Sohini RoyDouglas B Johnson

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Vaccines

Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.

Autoimmune Diseases

Autoimmune diseases occur as a result of an attack by the immune system on the body’s own tissues resulting in damage and dysfunction. There are different types of autoimmune diseases, in which there is a complex and unknown interaction between genetics and the environment. Discover the latest research on autoimmune diseases here.

Avian Influenza: Innate Immune Adjuvant

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Avian Influenza: Innate Immune Adjuvant (ASM)

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.